Prof. László Gulácsi, DSc
Prof. László Gulácsi, DSc
Budapest, Hungary, Óbuda University
Verified email at - Homepage
Cited by
Cited by
The economic impact of dementia in Europe in 2008—cost estimates from the Eurocode project
A Wimo, L Jönsson, A Gustavsson, D McDaid, K Ersek, J Georges, ...
International journal of geriatric psychiatry 26 (8), 825-832, 2011
Alopecia areata and health‐related quality of life: a systematic review and meta‐analysis
F Rencz, L Gulácsi, M Péntek, N Wikonkál, P Baji, V Brodszky
British journal of dermatology 175 (3), 561-571, 2016
The changing landscape of biosimilars in rheumatology
T Dörner, V Strand, P Cornes, J Gonçalves, L Gulácsi, J Kay, TK Kvien, ...
Annals of the rheumatic diseases 75 (6), 974-982, 2016
Statement of the European Pressure Ulcer Advisory Panel—pressure ulcer classification: differentiation between pressure ulcers and moisture lesions
T Defloor, L Schoonhoven, J Fletcher, K Furtado, H Heyman, M Lubbers, ...
Journal of Wound Ostomy & Continence Nursing 32 (5), 302-306, 2005
The state of the art in European research on reducing social exclusion and stigma related to mental health: a systematic mapping of the literature
S Evans-Lacko, E Courtin, A Fiorillo, M Knapp, M Luciano, AL Park, ...
European Psychiatry 29 (6), 381-389, 2014
EQ-5D in central and Eastern Europe: 2000–2015
F Rencz, L Gulácsi, M Drummond, D Golicki, V Prevolnik Rupel, J Simon, ...
Quality of Life Research 25, 2693-2710, 2016
Biosimilars for the management of rheumatoid arthritis: economic considerations
L Gulacsi, V Brodszky, P Baji, HU Kim, SY Kim, YY Cho, M Pentek
Expert review of clinical immunology 11 (sup1), 43-52, 2015
Epidemiology of osteoporosis related fractures in Hungary from the nationwide health insurance database, 1999–2003
M Pentek, C Horváth, I Boncz, Z Falusi, E Tóth, A Sebestyen, I Májer, ...
Osteoporosis international 19, 243-249, 2008
The implementation of quality management systems in hospitals: a comparison between three countries
C Wagner, L Gulácsi, E Takacs, M Outinen
BMC health services research 6, 1-11, 2006
Health technology assessment in Poland, the Czech Republic, Hungary, Romania and Bulgaria
L Gulácsi, AM Rotar, M Niewada, O Löblová, F Rencz, G Petrova, I Boncz, ...
The European journal of health economics 15, 13-25, 2014
Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary
E Herédi, F Rencz, O Balogh, L Gulácsi, K Herszényi, P Holló, H Jókai, ...
The European Journal of Health Economics 15, 111-119, 2014
Managing COVID-19 within and across health systems: why we need performance intelligence to coordinate a global response
D Kringos, F Carinci, E Barbazza, V Bos, K Gilmore, O Groene, L Gulácsi, ...
Health research policy and systems 18, 1-8, 2020
A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia
V Brodszky, F Rencz, M Péntek, P Baji, PL Lakatos, L Gulácsi
Expert review of pharmacoeconomics & outcomes research 16 (1), 119-125, 2016
Biological therapy in inflammatory bowel diseases: access in Central and Eastern Europe
F Rencz, M Péntek, M Bortlik, E Zagorowicz, T Hlavaty, A Śliwczyński, ...
World Journal of Gastroenterology: WJG 21 (6), 1728, 2015
Work disability and productivity loss in patients with inflammatory bowel diseases in Hungary in the era of biologics
MD Michael, A Bálint, BD Lovász, L Gulácsi, B Strbák, PA Golovics, ...
The European Journal of Health Economics 15, 121-128, 2014
Adherence to biologic DMARD therapies in rheumatoid arthritis
T Koncz, M Pentek, V Brodszky, K Ersek, E Orlewska, L Gulacsi
Expert opinion on biological therapy 10 (9), 1367-1378, 2010
The rituximab biosimilar CT-P10 in rheumatology and cancer: a budget impact analysis in 28 European countries
L Gulácsi, V Brodszky, P Baji, F Rencz, M Péntek
Advances in therapy 34, 1128-1144, 2017
Parallel valuation of the EQ-5D-3L and EQ-5D-5L by time trade-off in Hungary
F Rencz, V Brodszky, L Gulácsi, D Golicki, G Ruzsa, AS Pickard, EH Law, ...
Value in Health 23 (9), 1235-1245, 2020
Cost-of-illness of patients with systemic sclerosis in a tertiary care centre
T Minier, M Péntek, V Brodszky, A Ecseki, K Kárpáti, A Polgar, L Czirjak, ...
Rheumatology 49 (10), 1920-1928, 2010
Budget-impact analyses: a critical review of published studies
E Orlewska, L Gulácsi
Pharmacoeconomics 27, 807-827, 2009
The system can't perform the operation now. Try again later.
Articles 1–20